ArticleDiscover oncology2025
Clinical value and mechanism of CDKN2A in clear cell renal cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An agent-based learning model integrating sex differences in renal cell carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, with its incidence increasing annually. This study aims to investigate the role of the Cyclin-Dependent Kinase Inhibitor 2 A (CDKN2A) in ccRCC.
methodsWe analyzed ccRCC-related data from the TCGA and GEO databases. First, we systematically assessed the expression levels of CDKN2A and its correlation with clinical features, such as tumor staging and prognosis. Additionally, regarding biological function, we explored the relationship between CDKN2A expression and immune cell infiltration, along with the mechanisms underlying this relationship. We also examined the association between CDKN2A and drug sensitivity through drug sensitivity analysis. Furthermore, we experimentally validated the differential expression of CDKN2A in ccRCC and its impact on the cellular behaviors of ccRCC cells.
resultsThe results revealed that CDKN2A expression was significantly higher in ccRCC tissues compared to normal kidney tissues, affecting patient prognosis by modulating the tumor microenvironment. Moreover, based on data from the GDSC, and CTRP databases, we found that high CDKN2A expression was closely associated with sensitivity to certain small-molecule drugs. These drugs particularly target the MAPK pathway. Experimental findings indicated that CDKN2A promotes the proliferation, migration, and invasion of ccRCC cells via the MAPK pathway.
conclusionsOur study suggests that CDKN2A has an oncogenic role in ccRCC and may serve as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.